CAR T-Cell Therapy for Relapsed/ Refractory Non-Hodgkin’s Lymphoma: A Comprehensive Review

Frédérique St-Pierre, Leo I. Gordon*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

8 Scopus citations


Non-Hodgkin lymphoma (NHL) is the seventh most common type of malignancy worldwide, with approximately 544,000 cases diagnosed in 2020.1-3 The vast majority of NHLs are derived from B cells. The more than 80 subtypes of B-cell NHL are categorized according to their typical clinical course: indolent or aggressive.4 Aggressive B-cell NHLs that are refractory to first-line therapy or that relapse following initial treatment are historically associated with a poor prognosis, despite the use of salvage chemotherapy and autologous stem cell transplant.5 The advent of chimeric antigen receptor (CAR) T-cell therapy has changed the treatment paradigm for patients who have relapsed/ refractory aggressive B-cell NHL, with impressive response rates and the possibility for a durable remission in those whose disease has progressed despite multiple prior treatments.6-8 This review outlines current indications for CAR T-cell therapy, major toxicities, novel CARs under investigation, and future directions.

Original languageEnglish (US)
Pages (from-to)309-318
Number of pages10
JournalClinical Advances in Hematology and Oncology
Issue number5
StatePublished - May 2022


  • Chimeric antigen receptor T cell (CAR T cell)
  • lymphoma
  • non-Hodgkin lymphoma
  • relapsed/ refractory

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'CAR T-Cell Therapy for Relapsed/ Refractory Non-Hodgkin’s Lymphoma: A Comprehensive Review'. Together they form a unique fingerprint.

Cite this